This category D study has been completed. This phase I study tested the maximum tolerated dose of CI-1012, an antiretroviral agent that targets NCp7, a highly conserved, essential, multifunctional structural protein of the HIV virus. The drug also inhibits production of infectious virions. Data collected has been forwarded to the industrial sponsor for analysis.
Showing the most recent 10 out of 535 publications